Effects of some guanidino compounds on human cerebral arteries

Stroke

Volumn 30, Issue 10, 1999, Pages 2206-2211

  Segarra, G ^a   Medina, P ^a   Ballester, R M ^a   Lluch, P ^a   Aldasoro, M ^a   Vila, J M ^a   Lluch, S ^a,b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Cerebral arteries; Endothelium; Nitric oxide

Indexed keywords

AMINOGUANIDINE; ARGININE; ARGININE DERIVATIVE; GUANIDINE DERIVATIVE; METHYLGUANIDINE; N(G) METHYLARGININE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE;

ARTICLE; BLOOD VESSEL TONE; BRAIN ARTERY; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; RISK FACTOR; SMOOTH MUSCLE CONTRACTION; UREMIA; VASCULAR ENDOTHELIUM;

EID: 0032883086     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.10.2206     Document Type: Article

References (49)

1. Ignarro LJ, Byrns RE, Buga GM, Wood KS. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacological and chemical properties that are identical to those of nitric oxide radical. Circ Res. 1987;61:866-879.
2. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327: 524-526.
3. Rees DD, Palmer RMJ, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA. 1989;86: 3375-3378.
4. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 1989;2:997-1000.
5. Faraci FM, Brian JE. Nitric oxide and the cerebral circulation. Stroke. 1994; 25:692-703.
6. Aldasoro M, Martínez C, Vila JM, Medina P, Lluch S. Influence of endothelial nitric oxide on adrenergic contractile responses of human cerebral arteries. J Cereb Blood Flow Metab. 1996;16:623-628.
7. Toda N. Mediation by nitric oxide of neurally-induced human cerebral artery relaxation. Experientia. 1993;49:51-53.
8. Rees DD, Palmer RMJ, Hodson HF, Moncada S. A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol. 1989;96:418-424.
9. Bredt DS, Hwang PM, Snyder SH. Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature. 1990;347:768-770.
10. Nozaki K, Moskowitz MA, Maynard KI, Koketsu N, Dawson TM, Bredt DS, Snyder SH. Possible origins and distribution of immunoreactive nitric oxide synthase-containing nerve fibers in cerebral arteries. J Cereb Blood Flow Metab. 1993;13:70-79.
11. Faraci FM, Breese KR, Heistad DD. Nitric oxide contributes to dilatation of cerebral arterioles during seizures. Am J Physiol. 1993;265:H2209-H2212.
12. González C, Estrada C. Nitric oxide mediates the neurogenic dilatation of bovine cerebral arteries. J Cereb Blood Flow Metab. 1992;11:366-370.
13. Toda N, Ayajiki K, Okamura T. Cerebroarterial relaxations mediated by nitric oxide derived from endothelium and vasodilator nerves. J Vasc Res. 1993;30:61-67.
14. Jennekens FGI, Jennekens-Schinkel A. Neurological complications of dialytic patients. In: Maher JF, ed. Replacement of Renal Function by Dialysis. Boston, Mass: Kluwer Academic; 1989;972-983.
15. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis and prolonged maintenance hemodialysis. N Engl J Med. 1974;290: 679-685.
16. Odaka M. Mortality in chronic dialysis patients in Japan. Am J Kidney Dis. 1990;15:410-413.
17. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-575.
18. De Deyn PP, Marescau B, D'hooge R, Possemiers I, Nagler J, Mahler C. Guanidino compound levels in brain regions of non-dialyzed uremic patients. Neurochem Int. 1995;27:221-231.
19. May RC, Kelly RA, Mitch WE. Pathophysiology of uremia. In: Brenner BM, Rector FC, eds. The Kidney. Philadelphia, Pa: Saunders; 1991;1997-2018.
20. Matsumoto M, Kishikawa H, Mori A. Guanidino compounds in the sera of uraemic patients and in the sera and brain of experimental uraemic rabbit. Biochem Med. 1976;16:1-8.
21. Feng Q, Lu X, Fortin AJ, Pettersson A, Hedner T, Kline RL, Arnold JMO. Elevation of an endogenous inhibitor of nitric oxide synthesis in experimental congestive heart failure. Cardiovasc Res. 1998;37:667-675.
22. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci. 1998;62:2425-2430.
23. Aneman A, Backman V, Snygg J, von Bothmer C, Fandriks L, Pettersson A. Accumulation of an endogenous inhibitor of nitric oxide synthase during graded hemorrhagic shock. Circ Shock. 1994;44:111-114.
24. Sato J, Masuda H, Tamaoki S, Hamasaki H, Ishizaka K, Matsubara O, Azuma H. Endogenous asymmetrical dimethylarginine and hypertension associated with puromycin nephrosis. Br J Pharmacol. 1998;125:469-476.
25. Matsuoka H, Itoh S, Kimoto M, Kohno K, Tamai O, Wada Y, Yasukawa H, Iwami G, Okuda S, Imaizumi T. Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension. 1997;29:242-247.
26. MacAllister RJ, Whitley GSJ, Vallance P. Effects of guanidino and uremic compounds on nitric oxide pathways. Kidney Int. 1994;45:737-742.
27. G-methyiarginine, an inhibitor of endothelium-derived nitric oxide synthesis, is a potent pressor agent in the guinea pig: does nitric oxide regulate blood pressure in vivo?. Biochem Biophys Res Commun. 1989;160:881-886.
28. Whittle BJR. López-Belmonte J, Rees DD. Modulation of the vasodepressor actions of acetylcholine, bradykinin, substance P and endothelin in the rat by a specific inhibitor of nitric oxide formation. Br J Pharmacol. 1989;98: 646-652.
29. White RP, Deane C, Vallance P, Markus HS. Nitric oxide synthase inhibition in humans reduces cerebral blood flow but not the hyperemic response to hypercapnia. Stroke. 1998;29:467-472.
30. Misko TP, Moore WM, Kasten TP, Nickols GA, Corbett JA, Tilton RG, McDaniel ML, Williainson JR, Currie MG. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol. 1993; 233:119-125.
31. Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JL, Sweetland MA, Lancaster JR Jr, Williamson JR, McDaniel ML. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes. 1992;41:552-556.
32. MacAllister RJ, Fickling SA, Whitley GSJ, Vallance P. Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis. Br J Pharmacol. 1994;112:43-48.
33. MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann K-H, Ritz E. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant. 1996;11:2449-2452.
34. G-monomethyl-L-arginine in human end-stage renal failure patients on regular haemodialysis. Exp Physiol. 1996;81:475-481.
35. Taylor SG, Weston AH. Endothelium-derived hyperpolarising factor: a new endogenous inhibitor from the vascular endothelium. Trends Pharmacol Sci. 1988;9:272-274.
36. Chen G, Suzuki H, Weston AH. Acetylcholine releases endothelium-derived hyperpolarizing factor and EDRF from rat blood vessels. Br J Pharmacol. 1988;95:1165-1174.
37. Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB J. 1989;3:2007-2018.
38. Garland CJ, Plane F, Kemp BK, Cocks TM. Endothelium-dependem hyperpolarization: a role in the control of vascular tone. Trends Pharmacol Sci. 1995;16:23-30.
39. Mackert JL, Parsons AA, Wahl M, Schilling L. Mediation of endotheliumdependent relaxation: different response patterns in rat and rabbit basilar artery. Neurol Res. 1997;19:521-526.
40. Dong H, Waldron GJ, Cole WC, Triggle CR. Roles of calcium-activated and voltage-gated delayed rectifier potassium channels in endothelium-dependent vasorelaxation of the rabbit middle cerebral artery. Br J Pharmacol. 1998; 123:821-832.
41. Onoue H, Kaito N, Tokudome S, Abe T, Tashibu K, Nagashima H, Nakamura N. Investigation of postmortem functional changes in human cerebral arteries. J Cereb Blood Flow Metab. 1993;13:346-349.
42. Martín de Aguilera E, Vila JM, Irurzun A, Martínez MC, Martínez Cuesta MA, Lluch S. Endothelium-independent contractions of human cerebral arteries in response to vasopressin. Stroke. 1990;21:1689-1693.
43. Martín de Aguilera E, Irurzun A, Vila JM, Aldasoro M, Galeote MS, Lluch S. Role of endothelium and calcium channels in endothelin-induced contraction of human cerebral arteries. Br J Pharmacol. 1990;99:439-440.
44. Kanamaru K, Waga S, Kojima S, Fujimoto K, Niwa S. Endothelium-dependent relaxation of canine basilar arteries, II: inhibition by hemoglobin and cerebrospinal fluid from patients with aneurysmal subarachnoid hemorrhage. Stroke. 1987;18:938-943.
45. Radomski MW, Palmer RMJ, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol. 1987;92:181-187.
46. De Deyn PP, Marescau B, Cuykens JJ, Van Gorp L, Lowenthal A. Guanidino compounds in serum and cerebrospinal fluid of nondialyzed patients with renal insufficiency. Clin Chim Acta. 1987;167:81-88.
47. De Deyn PP, Marescau B, Swartz RD, Hogaerth R, Possemiers I, Lowenthal A. Serum guanidino compound levels and clearances in uremic patients treated with continuous ambulatory peritoneal dialysis. Nephron. 1990;54: 307-312.
48. Postiglione A, Faccenda F, Gallotta G, Rubba P, Federico S. Changes in middle cerebral artery blood velocity in uremic patients after hemodialysis. Stroke. 1991;22:1508-1511.
49. Hata R, Matsumoto M, Handa N, Terakawa H, Sugitani Y, Kamada T. Effects of hemodialysis on cerebral circulation evaluated by transcranial doppler ultrasonography. Stroke. 1994;25:408-412.